Compare Hyatt Hotels Corporation (H) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Sana Biotechnology Inc — how do they compare? Hyatt Hotels Corporation trades at $191.5 (market cap $17.85B), while Sana Biotechnology Inc trades at $3.23 (market cap $873.84M). The key difference: Hyatt Hotels Corporation is far larger — about 20.4× Sana Biotechnology Inc's market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| H | SANA | |
|---|---|---|
Market Cap | $17.85B | $873.84M |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $5.92 |
52-Week Low | $135.01 | $2.68 |
Enterprise Value | $21.69B | $848.03M |
Dividend Yield | 0.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $189.75, down 0.47% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $198. Recent earnings show mixed results, with Q2 2026 expected at $0.89 EPS. The company maintains strategic expansions, including new hotel openings and partnerships, while facing profitability challenges with a negative net income margin of -0.48% in 2025.
The stock presents a moderate buy opportunity with analyst support, but risks include declining cash flows and elevated debt. Upside hinges on execution of growth initiatives and improved earnings, while macroeconomic pressures on travel demand pose headwinds. Investors should weigh the 37.5% buy rating against fundamental weaknesses.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
